Daiichi sankyo and vascepa

Quote






I was talking to an ABBVIE rep in the PA area who has been with the company for years and all ABBVIE reps are being trained and certified in LIPIDOLOGY by the National Speaker of LIPIDOLOGISTS.

Rumor is ABBVIE will make the bid once NCE is finalized.
 






Anonymous said:
I was talking to an ABBVIE rep in the PA area who has been with the company for years and all ABBVIE reps are being trained and certified in LIPIDOLOGY by the National Speaker of LIPIDOLOGISTS.

Rumor is ABBVIE will make the bid once NCE is finalized.
Click to expand...

Yes, and they intend to expand into future indications beyound lipids, e.g. to prevent aggression and depression like they do already succesfully with HUMIRA
 


















Anonymous said:
I dunno. Kristie B. is AMRN 's new Director of Trade. She is from Daiichi. I think any deal between daiichi & Amarin is more a partnership for a combo pill.
Click to expand...

The only problem is that there are no interest or market for such a pill.
It will never happen.

And to think that the Japanese would have ANY interest in Vascepa, a product THEY developed decades ago is sheer lunacy!

In fact, large Japanese pharmas have never been interested in selling highly concentrated EPE-E as medicine, instead Takeda are introducing Lovaza in the Japanese market as we speak!

Wake up you naive dreamers, Amarin is DESTINED to fail right from the beginning!!

Profits from their ONLY product is impossible with generic Lovaza soon on the market!

YOU amateurs are NOT smarter than GSK, Abbott, Takeda et. al!
 






Anonymous said:
The only problem is that there are no interest or market for such a pill.
It will never happen.

And to think that the Japanese would have ANY interest in Vascepa, a product THEY developed decades ago is sheer lunacy!

In fact, large Japanese pharmas have never been interested in selling highly concentrated EPE-E as medicine, instead Takeda are introducing Lovaza in the Japanese market as we speak!

Wake up you naive dreamers, Amarin is DESTINED to fail right from the beginning!!

Profits from their ONLY product is impossible with generic Lovaza soon on the market!

YOU amateurs are NOT smarter than GSK, Abbott, Takeda et. al!
Click to expand...

You are a short seller and a moron and there is no place for you on this board or any board. Get the F out you stupid piece of worthless dog shit.
 






Anonymous said:
The only problem is that there are no interest or market for such a pill.
It will never happen.

And to think that the Japanese would have ANY interest in Vascepa, a product THEY developed decades ago is sheer lunacy!

In fact, large Japanese pharmas have never been interested in selling highly concentrated EPE-E as medicine, instead Takeda are introducing Lovaza in the Japanese market as we speak!

Wake up you naive dreamers, Amarin is DESTINED to fail right from the beginning!!

Profits from their ONLY product is impossible with generic Lovaza soon on the market!

YOU amateurs are NOT smarter than GSK, Abbott, Takeda et. al!
Click to expand...


The poster of this quote is one of the idiot AMRN bashers from the Yahoo Message Board, ID: Kolemup, Heidi, OmegaOracle, etc.... No proof or link is ever posted posted to back up what they write, just more of the same stupid negative content they post everywhere.
 






Anonymous said:
The only problem is that there are no interest or market for such a pill.
It will never happen.

And to think that the Japanese would have ANY interest in Vascepa, a product THEY developed decades ago is sheer lunacy!

In fact, large Japanese pharmas have never been interested in selling highly concentrated EPE-E as medicine, instead Takeda are introducing Lovaza in the Japanese market as we speak!

Wake up you naive dreamers, Amarin is DESTINED to fail right from the beginning!!

Profits from their ONLY product is impossible with generic Lovaza soon on the market!

YOU amateurs are NOT smarter than GSK, Abbott, Takeda et. al!
Click to expand...

Looks like Amarin is smart enough to conduct multiple studies in inflammatory biomarkers:

http://www.ncbi.nlm.nih.gov/pubmed/23325450

"Am J Cardiovasc Drugs. 2013 Jan 17. [Epub ahead of print]
Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies.
Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN.
Source
Louisville Metabolic and Atherosclerosis Research Center, 3288 Illinois Avenue, Louisville, KY, 40213, USA, HBaysMD@aol.com.
Abstract
BACKGROUND:
Icosapent ethyl (IPE) is a high-purity prescription form of eicosapentaenoic acid ethyl ester approved by the US Food and Drug Administration as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. In addition to TG-lowering effects, IPE also reduces non-high-density lipoprotein cholesterol and apolipoprotein B levels without significantly increasing low-density lipoprotein cholesterol (LDL-C) in patients with very high TG levels ≥500 mg/dL (MARINE study) and in patients with well-controlled LDL-C and residually high TG levels 200-500 mg/dL (ANCHOR study). This analysis examined the effect of IPE on inflammatory markers in patients from MARINE and ANCHOR.
METHODS:
MARINE (N = 229) and ANCHOR (N = 702) were Phase III, double-blind studies that randomized hypertriglyceridemic patients to IPE 4 g/day, 2 g/day, or placebo. This analysis assessed the median placebo-adjusted percentage change from baseline in markers representing various stages of atherosclerotic inflammation such as intercellular adhesion molecule-1 (ICAM-1), oxidized low-density lipoprotein (Ox-LDL), lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hsCRP).
RESULTS:
Compared to placebo, IPE 4 g/day significantly decreased Ox-LDL (13 %, p < 0.0001, ANCHOR), Lp-PLA(2) (14 %, p < 0.001, MARINE; 19 %, p < 0.0001, ANCHOR), and hsCRP levels (36 %, p < 0.01, MARINE; 22 %, p < 0.001, ANCHOR), but did not significantly change ICAM-1 and IL-6 levels. In the MARINE study, IPE 2 g/day did not significantly change ICAM-1, Ox-LDL, Lp-PLA(2), IL-6, or hsCRP levels. Also, compared to placebo in the ANCHOR study, IPE 2 g/day significantly decreased Lp-PLA(2) levels (8 %, p < 0.0001), but did not significantly change levels of other assessed inflammatory markers.
CONCLUSION:
Compared to placebo, in hypertriglyceridemic patients, IPE 4 g/day significantly decreased Ox-LDL, Lp-PLA(2), and hsCRP levels."
 




































Anonymous said:
Yes, and they intend to expand into future indications beyound lipids, e.g. to prevent aggression and depression like they do already succesfully with HUMIRA
Click to expand...

Yeah, Vascepa will also become an alternative to failed bardoxolone methyl, Ethyl-EPA is a great NRF2 modulator and diabetic nephropathy is a multi billion dollar market, in addition, most ckd patients have elevated triglycerides - first data could be obtained via phase IV studies
 






All you people on this board are idiots. Vascepa will take some time to gain momentum out in the market. If Amarin is smart they will not follow PHARMA guidelines. If they use local advocates in the field this product will take off. Find those 10 decile doctors and take them out and have them push the product through formulary. Part D is going to be huge for Amarin, so I wish you all the best. I have told every account I call on especially my Cards. Best of Luck
 
























No one is buying and it's not based on NCE. COGs are too high. Anchor isn't multibillion dollar potential. Bottom line- as the saying goes you put lipstick on a pig, it's still a pig.
Look to Merck, Novartis, Amgen for a new job!
 






Top Bottom
Back
Quote